While there are no current clinical trials that investigate the blocking of the PVR-TIGIT axis in neuroblastoma yet, it could be a promising approach, particularly in combination with the already established anti-GD2 immunotherapy or with GD2-specific CAR T cell strategies [33]. Here, TIGIT is linked to neuroblastoma.